Trump Administration Moves to Rein In 340B Hospital Abuse

A federal program created to help vulnerable patients access affordable medications has increasingly become a financial windfall for large tax-exempt hospital systems. The Trump administration's proposed 340B Rebate Model Pilot Program seeks to bring greater transparency and accountability to a program that now exceeds $80 billion in annual discounted drug purchases.

The Health Resources and Services Administration recently announced a request for information on a pilot program that would test a rebate-based approach within the 340B Drug Pricing Program. Supporters argue the proposal would strengthen oversight and help ensure that program benefits are reaching the patients Congress intended to serve.

A Program That Has Drifted from Its Original Purpose

Congress established the 340B Drug Pricing Program to allow certain hospitals and safety-net providers to purchase prescription drugs at steep discounts. The expectation was that those savings would support care for low-income and underserved patients.

Over time, however, concerns have grown that many hospitals are using the program in ways that do little to directly benefit vulnerable patients. Rather than passing discounted prices through to patients, hospitals often acquire drugs at deeply reduced 340B prices while billing insurance companies, taxpayers, and patients at much higher rates.

The difference between the discounted acquisition cost and the reimbursement received is frequently retained by the hospital system. Critics argue that this practice has transformed a patient-focused assistance program into a significant source of revenue for large healthcare organizations.

Questions About Tax-Exempt Hospitals and 340B Profits

The issue is particularly significant because many participating hospitals operate as tax-exempt nonprofit institutions. In exchange for favorable tax treatment, these hospitals are expected to provide charity care and other community benefits.

The 340B program was designed to support that mission. Instead, critics contend that some hospital systems have used the program to generate substantial margins while providing limited evidence that savings are being directed toward vulnerable patients.

As the program has expanded, policymakers have increasingly questioned whether existing oversight mechanisms are sufficient to ensure accountability.

Why the Rebate Pilot Matters

The proposed rebate model would introduce additional verification and reporting requirements into the 340B process. Supporters believe the approach would help validate patient eligibility, reduce the risk of duplicate discounts, and provide regulators with better information about how the program operates.

A recent congressional letter supporting the pilot noted that lawmakers have limited visibility into many 340B transactions despite the program's enormous size. Greater transparency would make it easier to determine whether discounts are reaching eligible patients and whether participating institutions are complying with the program's intended purpose.

The rebate model would also provide policymakers with more reliable data as they evaluate potential reforms to a program that has grown dramatically over the past decade.

A Needed Step Toward Accountability

The debate over 340B is not about ending assistance for vulnerable patients. It is about ensuring that a program created to help those patients is operating as intended.

Programs of this size and importance should be able to demonstrate that public benefits are supporting patient care rather than simply increasing hospital revenues. Stronger oversight can help restore confidence that the program is serving its original mission.

CFE Takeaway

The 340B Drug Pricing Program was created to help vulnerable patients access affordable medications, not to provide large tax-exempt hospital systems with another source of revenue. The Trump administration's 340B Rebate Model Pilot Program is a sensible step toward greater transparency, stronger oversight, and improved program integrity. Policymakers should support reforms that ensure 340B discounts benefit patients rather than hospital bottom lines.